Core Insights - WuXi Biologics (2269.HK) reported a strong performance for the first half of 2025, with revenue reaching RMB 9.95 billion, a year-on-year increase of 16.1% [1] - Net profit grew by 54.8% to RMB 2.76 billion, with profit attributable to shareholders increasing by 56.0% to RMB 2.34 billion [1] - The gross margin improved by 3.6 percentage points to 42.7%, with adjusted gross profit amounting to RMB 4.54 billion [1] - The company raised its full-year revenue guidance for 2025 to a growth range of 14%-16% [1] Business Segments Performance - All three major business segments—Research (R), Development (D), and Manufacturing (M)—experienced rapid growth in the first half of 2025 [1] - The research services segment enabled over 50 molecular projects, with potential milestone payments and sales commissions expected to significantly enhance long-term profit growth [1] - In the development segment, preclinical revenue increased by 35.2%, with the proprietary cell line development platform WuXia having over 600 projects eligible for potential cell line royalties [1] - The manufacturing segment saw a 24.9% year-on-year increase in revenue from Phase III clinical and commercial production, with plans to complete 25 PPQs by 2025, laying a solid foundation for future growth [1]

Core Viewpoint - WuXi Biologics (02269) has raised its full-year revenue guidance for 2025 from 12%-15% to 14%-16%, indicating strong growth potential in its financial performance [1] Financial Performance - The company reported a 16.1% year-on-year increase in revenue for the first half of the year, reaching RMB 9.95 billion, with a 20.2% growth in continuing operations revenue [1] - EBITDA increased by 50.5% year-on-year to RMB 4.22 billion, while net profit rose by 54.8% to RMB 2.76 billion [1] - Profit attributable to shareholders grew by 56.0% to RMB 2.34 billion, and adjusted net profit increased by 11.6% to RMB 2.84 billion, with an adjusted net profit margin of 28.5% [1] Project and Order Growth - The company signed 86 new comprehensive projects in the first half of the year, setting a historical record for the same period, bringing the total number of comprehensive projects to 864 [1] - The total value of uncompleted orders reached USD 20.34 billion, with an increase of USD 4.21 billion in uncompleted orders over the past three years, indicating a significant growth in revenue expectations [1] Market Environment - The overall innovation drug investment and financing market is recovering, and active licensing transactions are expected to support the continued growth of WuXi Biologics and other leading CXO companies [1]

Core Viewpoint - WuXi Biologics reported a strong performance for the first half of 2025, with revenue reaching 9.95 billion RMB, a year-on-year increase of 16.1%, and a net profit growth of 54.8% to 2.76 billion RMB, indicating robust business growth and a positive outlook for the future [1][2]. Financial Performance - The company achieved a gross margin of 42.7%, up 3.6 percentage points year-on-year [1]. - Adjusted net profit increased by 11.6% to 2.84 billion RMB, while profit attributable to shareholders rose by 56.0% to 2.34 billion RMB [1]. - WuXi Biologics raised its full-year revenue guidance for 2025 to a growth range of 14%-16% [1]. Business Development - The company signed 86 new comprehensive projects in the first half of 2025, setting a historical record and bringing the total number of projects to 864 [1]. - Over 70% of new projects focus on ADC (Antibody-Drug Conjugates) and bispecific/multispecific antibodies, highlighting the high demand in these areas [1]. - The conversion rate from R&D to development and manufacturing exceeds 90%, showcasing strong client relationships and business integration [4]. Market Position and Strategy - WuXi Biologics has a significant order backlog of 20.34 billion USD, with over 4.21 billion USD in unfulfilled orders expected in the next three years, reinforcing the stability and growth potential of its core business [2]. - The company has evolved from a traditional service provider to a platform company that empowers global innovative biopharmaceutical development [4]. - The firm’s unique CRDMO business model creates substantial competitive barriers that are difficult to replicate [4]. Technological Innovation - WuXi Biologics launched several advanced platforms in 2023, including EffiXTM and WuXiaHigh2.0, enhancing its production capabilities [6]. - The company’s automated production line has achieved a breakthrough in continuous production, significantly increasing output [6]. External Environment and Market Trends - The capital market for innovative drugs is recovering, with significant increases in financing activities in the healthcare sector [2]. - Policy updates in China are expected to stimulate domestic innovative drug development, benefiting WuXi Biologics as a leading CXO enterprise [7]. Valuation and Investment Potential - As of August 18, the company's PE ratio reached 35.35, indicating a recovery in valuation, yet it remains below the historical average, suggesting potential for further appreciation [8]. - The company’s stock buyback program has increased its net asset value per share to 11.28 HKD, enhancing its investment appeal [7].

Core Insights - WuXi Biologics reported a revenue of 9.95 billion RMB for the first half of 2025, marking a year-on-year growth of 16.1% [1] - The company raised its full-year revenue guidance for 2025 to a range of 14%-16% [1] - The company signed 86 new comprehensive projects in the first half of 2025, setting a historical record, with a total of 864 projects [1][2] Financial Performance - Gross profit margin increased by 3.6 percentage points to 42.7% year-on-year [1] - Net profit rose by 54.8% to 2.76 billion RMB, leading to a 56.0% increase in profit attributable to shareholders, amounting to 2.34 billion RMB [1] - Adjusted net profit grew by 11.6% to 2.84 billion RMB [1] Business Structure and Growth Drivers - The acceleration of the transition from R&D to development and manufacturing is a key driver of the company's rapid growth [1] - Over 70% of new projects focus on ADC (antibody-drug conjugates) and bispecific/multispecific antibodies, indicating high demand in these areas [2] - The company has a backlog of unfulfilled service orders totaling 20.34 billion USD, with over 4.21 billion USD expected in the next three years [2] Market Environment and Investment Trends - The CXO industry is experiencing a significant uptrend in investment, with 592 financing rounds completed in the first half of the year, totaling 36.372 billion RMB, a year-on-year increase of 17.54% [3] - The stock price of WuXi Biologics has increased by 75% year-to-date, reflecting strong investor confidence [3] Competitive Advantages - WuXi Biologics has established a unique CRDMO business model, evolving from a traditional service provider to a platform company supporting global biopharmaceutical innovation [4] - The company maintains a high customer conversion rate of over 90% from R&D to development and manufacturing [4] - The company has developed proprietary technology platforms across R, D, and M, enhancing its competitive edge [5] Technological Innovation - WuXi Biologics launched several new technology platforms in the first half of the year, including EffiX and WuXiaHigh2.0, which are expected to improve production efficiency [6] - The company’s production capabilities have been validated with recent approvals from the EU and FDA for commercial production [6] External Environment and Future Outlook - Positive changes in the external environment, including expectations of interest rate cuts by the Federal Reserve, are likely to attract more capital into the pharmaceutical innovation sector [7] - The company has repurchased 132 million shares, amounting to 2.29 billion HKD, which has increased its net asset value per share to 11.28 HKD [7] Valuation and Investment Potential - As of August 18, the company's PE ratio reached 35.35, surpassing its three-year historical average of 31.89 [8] - The current valuation remains below that of global peers, indicating significant upside potential, with a target price of 77.57 HKD based on historical averages [8]

项目订单方面，未完成订单总额超200亿美元，达203.4亿美元。3年内未完成订单总额增长至42.1亿美 元，近期收入预期增长可观。 智通财经APP获悉，8月19日，药明生物(02269)发布2025年中期业绩，上半年收益同比增长16.1%至99.5 亿元，持续经营业务收益增长20.2%。公司整体盈利能力继续增强，EBITDA同比增长50.5%至42.2亿 元，纯利同比增长54.8%至人民币27.6亿元，公司拥有人应占纯利增长56.0%至人民币23. 4亿元。经调整 纯利同比增长11.6%至人民币28.4亿元，经调整纯利率达28.5%。业绩快速增长支撑药明生物上调2025全 年收入指引至14%-16%。 ...

此外，上半年新签综合项目86个，创同期历史新高，推高综合项目总数至864个。未完成订单总额达 203.4亿美元，三年内未完成订单总额增长至42.1亿美元，近期收入预期增长可观。 此外，整个创新药投融资市场回暖、授权交易活跃等多重利好因素，也将支撑药明生物等CXO龙头企 业业务持续增长。 智通财经APP获悉，药明生物(02269)在刚刚发布的2025年中期业绩报告中，将其2025年全年收入指引从 12%-15%上调至14%-16%。 公司核心财务数据释放加速增长的积极信号，上半年收益同比增长16.1%至99.5亿元，持续经营业务收 益增长20.2%。公司整体盈利能力继续增强，EBITDA同比增长50.5%至42.2亿元，纯利同比增长54.8% 至人民币27.6亿元，公司拥有人应占纯利增长56.0%至人民币23. 4亿元。经调整纯利同比增长11.6%至人 民币28.4亿元，经调整纯利率达28.5%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 WUXI BIOLOGICS (CAYMAN) INC. 藥明生物技術有限公司* 於晚上八時正（香港時間）以英文進行的電話會議： https://jefferies.zoom.us/webinar/register/WN_A74otDPyQciXKWgDXMAwCA 請在電話會議進行前使用上文提供的鏈接完成線上註冊程序。 （於開曼群島註冊成立的有限公司） （股份代號：2269） 內幕消息 二零二五年中期業績簡報 本公告由WuXi Biologics (Cayman) Inc.藥明生物技術有限公司*（「本公司」）根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第 571章《證券及期貨條例》第XIVA部項下內幕消息條文（定義見上市規則）而作出。 為使本公司股東及潛在投資者能夠更深入、更全面地了解其二零二五年中期 業績及業務營運，本公司將於二零二五年八月二十日上午九時正及晚上八時 ...

Core Insights - WuXi Biologics (02269) reported a 16.1% year-on-year revenue growth for the first half of 2025, reaching RMB 9.95 billion, with a 20.2% increase in revenue from continuing operations [1] - The company's overall profitability improved significantly, with EBITDA rising by 50.5% to RMB 4.22 billion and net profit increasing by 54.8% to RMB 2.76 billion [1] - Adjusted net profit grew by 11.6% to RMB 2.84 billion, with an adjusted net profit margin of 28.5% [1] - The strong performance led the company to raise its full-year revenue guidance for 2025 to a range of 14%-16% [1] - The total value of unfulfilled orders exceeded USD 20.34 billion, with unfulfilled orders over the next three years increasing to USD 4.21 billion, indicating a substantial growth in revenue expectations [1]

截至2025年6月30日，药明生物一体化平台上的临床III期及商业化生产项目分别达67和24个，收益同比 增24.9%。此外，其研究服务已经赋能50多个分子项目，并有权益收取未来的潜在里程碑付款和销售提 成，将显著提升公司长期利润增长。其为GSK开发的一款分子已进入临床阶段，成为药明生物赋能的第 四个进入临床阶段的TCE项目。 项目订单方面，药明生物未完成订单总额超200亿美元，达203.4亿美元。3年内未完成订单总额增长至 42.1亿美元，近期收入预期增长可观。 药明生物(02269)2025年中期业绩发布，上半年新签综合项目86个，创同期历史新高，推高综合项目总 数至864个，进一步巩固其拥有业界最大的复杂生物药产品线之一的领先地位。新签项目中，双抗多 抗、ADC占比超70%，引领创新生物药两大黄金赛道。业绩快速增长支撑药明生物上调2025全年收入指 引至14%-16%。 ...

截至2025年6月30日，药明生物一体化平台上的临床III期及商业化生产项目分别达67和24个，收益同比 增24.9%。此外，其研究服务已经赋能50多个分子项目，并有权益收取未来的潜在里程碑付款和销售提 成，将显著提升公司长期利润增长。其为GSK开发的一款分子已进入临床阶段，成为药明生物赋能的第 四个进入临床阶段的TCE项目。 项目订单方面，药明生物未完成订单总额超200亿美元，达203.4亿美元。3年内未完成订单总额增长至 42.1亿美元，近期收入预期增长可观。 智通财经APP获悉，药明生物(02269)2025年中期业绩发布，上半年新签综合项目86个，创同期历史新 高，推高综合项目总数至864个，进一步巩固其拥有业界最大的复杂生物药产品线之一的领先地位。新 签项目中，双抗\多抗、ADC占比超70%，引领创新生物药两大黄金赛道。业绩快速增长支撑药明生物 上调2025全年收入指引至14%-16%。 ...